You just read:

Phase III Trial of Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival

News provided by

Bayer HealthCare

03 Apr, 2012, 02:31 ET